The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance

被引:27
|
作者
Choi, Bo-Hyun [1 ]
Kim, Jin Myung [2 ]
Kwak, Mi-Kyoung [2 ,3 ]
机构
[1] Daegu Catholic Univ, Sch Med, Dept Pharmacol, Daegu 42472, South Korea
[2] Catholic Univ Korea, Dept Pharm, Grad Sch, Gyeonggi Do 14662, South Korea
[3] Catholic Univ Korea, Dept Pharm, Grad Sch, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea
基金
新加坡国家研究基金会;
关键词
NRF2; KEAP1; Cancer; Cancer stem cell; Therapy resistance; TRANSCRIPTION FACTOR NRF2; HEME OXYGENASE-1 EXPRESSION; LUNG-CANCER; BREAST-CANCER; OXIDATIVE STRESS; SIDE POPULATION; SELF-RENEWAL; HEPATOCELLULAR-CARCINOMA; ACTIVATION PROMOTES; SIGNALING PATHWAY;
D O I
10.1007/s12272-021-01316-8
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The transcription factor nuclear factor erythroid 2-like 2 (NEF2L2; NRF2) plays crucial roles in the defense system against electrophilic or oxidative stress by upregulating an array of genes encoding antioxidant proteins, electrophile/reactive oxygen species (ROS) detoxifying enzymes, and drug efflux transporters. In contrast to the protective roles in normal cells, the multifaceted role of NRF2 in tumor growth and progression, resistance to therapy and intratumoral stress, and metabolic adaptation is rapidly expanding, and the complex association of NRF2 with cancer signaling networks is being unveiled. In particular, the implication of NRF2 signaling in cancer stem cells (CSCs), a small population of tumor cells responsible for therapy resistance and tumor relapse, is emerging. Here, we described the dark side of NRF2 signaling in cancers discovered so far. A particular focus was put on the role of NRF2 in CSCs maintenance and therapy resistance, showing that low ROS levels and refractory drug response of CSCs are mediated by the activation of NRF2 signaling. A better understanding of the roles of the NRF2 pathway in CSCs will allow us to develop a novel therapeutic approach to control tumor relapse after therapy.
引用
收藏
页码:263 / 280
页数:18
相关论文
共 50 条
  • [21] Understanding the Role of NRF2 Signalling in Cancer
    Singh, Pooja G.
    Gopenath, T. S.
    Basalingappa, Kanthesh M.
    Bharadwaj, M. N. Ramesh
    Ilangovan, R.
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2022, 23 (10) : 672 - 683
  • [22] Role of NRF2 in HIF-2α-mediated cancer stem cell phenotype
    Kwak, Mi-Kyoung
    Hallis, Steffanus P.
    CANCER RESEARCH, 2024, 84 (06)
  • [23] The Role of Nrf2 signaling in cancer stem cells: From stemness and self-renewal to tumorigenesis and chemoresistance
    Kahroba, Houman
    Shirmohamadi, Masoud
    Hejazi, Mohammad Saeid
    Samadi, Nasser
    LIFE SCIENCES, 2019, 239
  • [24] Survival factor Nrf2 and its role in chemoresistance of ovarian cancer cells
    Shim, Gi-Seong
    Manandhar, Sarala
    Shin, Dongha
    You, Aram
    Kwak, Mi-kyoung
    CANCER RESEARCH, 2009, 69
  • [25] Nrf2 REGULATION AND ITS DUAL ROLE IN CANCER
    Wu, Tongde
    Harder, Bryan
    Guinea, Elisa Rojo De La Vega
    Tao, Shasha
    Tian, Wang
    Jiang, Tao
    Ooi, Aikseng
    Chapman, Eli
    Zhang, Donna D.
    FREE RADICAL BIOLOGY AND MEDICINE, 2014, 76 : S6 - S6
  • [26] Role of NRF2 in Colorectal Cancer Prevention and Treatment
    Li, Jiaxiang
    Wang, Dan
    Liu, Yifei
    Zhou, Yanhong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [27] The Multifaceted Roles for NRF2 in Regulating Tumor Development and Progression: An Update
    Kim, Su -Jung
    Surh, Young-Joon
    MOLECULES AND CELLS, 2023, 46 (03) : 131 - 132
  • [28] The Dual Role of NRF2 in Colorectal Cancer: Targeting NRF2 as a Potential Therapeutic Approach
    Hu, Mengyun
    Yuan, Lingling
    Zhu, Jie
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 : 5985 - 6004
  • [29] Growth on HNE modified collagen induce Nrf2 in breast cancer stem cells
    Pezdirc, Iskra
    Vrancic, Josip
    Milkovic, Lidija
    Djakovic, Nikola
    Gasparovic, Ana Cipak
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 124 : 573 - 573
  • [30] Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation
    Wen-Chen Ouyang
    Yi-Wen Liao
    Pei-Ni Chen
    Kai-Hsi Lu
    Cheng-Chia Yu
    Pei-Ling Hsieh
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 411 - 419